Skip to Content
Discovering the causes of cancer and the means of prevention

Publications Search - Abstract View

Title: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.
Authors: Schmidt L,  Duh FM,  Chen F,  Kishida T,  Glenn G,  Choyke P,  Scherer SW,  Zhuang Z,  Lubensky I,  Dean M,  Allikmets R,  Chidambaram A,  Bergerheim UR,  Feltis JT,  Casadevall C,  Zamarron A,  Bernues M,  Richard S,  Lips CJ,  Walther MM,  Tsui LC,  Geil L,  Orcutt ML,  Stackhouse T,  Lipan J,  Slife L,  Brauch H,  Decker J,  Niehans G,  Hughson MD,  Moch H,  Storkel S,  Lerman MI,  Linehan WM,  Zbar B
Journal: Nat Genet
Date: 1997 May
Branches: ITEB
PubMed ID: 9140397
PMC ID: not available
Abstract: Hereditary papillary renal carcinoma (HPRC) is a recently recognized form of inherited kidney cancer characterized by a predisposition to develop multiple, bilateral papillary renal tumours. The pattern of inheritance of HPRC is consistent with autosomal dominant transmission with reduced penetrance. HPRC is histologically and genetically distinct from two other causes of inherited renal carcinoma, von Hippel-Lindau disease (VHL) and the chromosome translocation (3;8). Malignant papillary renal carcinomas are characterized by trisomy of chromosomes 7, 16 and 17, and in men, by loss of the Y chromosome. Inherited and sporadic clear cell renal carcinomas are characterized by inactivation of both copies of the VHL gene by mutation, and/or by hypermethylation. We found that the HPRC gene was located at chromosome 7q31.1-34 in a 27-centimorgan (cM) interval between D7S496 and D7S1837. We identified missense mutations located in the tyrosine kinase domain of the MET gene in the germline of affected members of HPRC families and in a subset of sporadic papillary renal carcinomas. Three mutations in the MET gene are located in codons that are homologous to those in c-kit and RET, proto-oncogenes that are targets of naturally-occurring mutations. The results suggest that missense mutations located in the MET proto-oncogene lead to constitutive activation of the MET protein and papillary renal carcinomas.